Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05636787 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients

Study acronym: TreoMel
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Start date: May 4, 2023 to Jun 6, 2023v4 Show 4 more changesShow less
    • Interventions: Melphalan (Drug), Melphalan and Treosulfan (Drug) to Melphalan (Drug), Treosulfan (Drug)
    • Secondary endpoints: 6 to 9
    • Study description revised
    • Study title revised
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2023 to May 4, 2023
    v3
  4. Study description expanded, about 17 words
    • Study title revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
Trial Details
NCT Number NCT05636787
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov